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Abstract
Background and Aims: Crigler-Najjar syndrome (CNS) is a disorder of bilirubin conjugation leading to brain damage and death without treatment. Although cohort studies
of limited size have been published, uncertainty about outcome, co-morbidities, occurence of liver fibrosis and treatment outcome remains. With this worldwide cohort
study, we aim to add substantial knowledge to the previously published data.
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Methods: Anonymized retrospective data of CNS patients were collected in a web-
based registry platform.
Results: Clinical data of 221 CNS patients (46% female, severe phenotype n = 209)
were collected. At the time of analysis, 59 CNS patients were deceased. Mean serum
total bilirubin (TB) was 300 μmoL/L, mean conjugated bilirubin (CB) 14.4 μmoL/L.
The incidence of neurologic symptoms was 10.7%. Elevated alanine aminotransferase

Handling Editor: Luca Valenti

(ALT, >70 U/L) was present in 43/221 (19.5%) and the mean gamma-glutamyl transpeptidase (GGT) was 54 U/L. CB and TB did not correlate with aspartate aminotransferase (AST), ALT or GGT. TB was higher in males than in females (316 vs. 287 μmol/L;
p < .001). Cholelithiasis was detected in 14 of 91 ultrasound examinations. In 5 of 31
CNS patients with liver fibrosis evaluation advanced fibrosis and significant higher
AST were detected. Liver transplantation (LT) was performed in 26 CNS patients at
the median age of 9 years (0–32 years). A subgroup of 75 CNS patients showed high
TB (444 ± 141 μmoL/L) and high mortality/morbidity because of inadequate access
to treatment.
Conclusions: This largest cohort of CNS patients to date shows the urgent need to
globally expand access to therapy and gives insight into the clinical course and outcome of different treatment strategies. However, some questions need ongoing examination, especially regarding liver fibrosis and the timing of LT.
KEYWORDS

encephalopathy, liver transplantation, phototherapy, UGT1A1, unconjugated hyperbilirubinemia
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I NTRO D U C TI O N

affected patients without residual UGT1A1 activity died soon after
birth.1 Optimization of the PT units made it possible to prevent brain

Crigler-Najjar syndrome (CNS; OMIM 218800) is an ultra-rare

damage and to keep patients alive, until liver transplantation (LT). A

(<1/1 million newborns) autosomal recessive monogenic disorder

registry published 25 years ago revealed orthotopic LT and daily PT

of bilirubin conjugation that results in the accumulation of neuro-

as the two main treatment methods.5 Patients with some degree of

1

toxic unconjugated bilirubin (UCB). Accumulation of UCB in CNS is

residual UGT1A1 activity can be treated with phenobarbital (PB) to

caused by uridine 5′-diphosphate glucuronyltransferase (UGT1A1)

induce the expression of the residual UGT1A1.6

deficiency, a non-secreted intracellular enzyme, mainly located in

Epidemiological evidence revealed that patients with CNS carry

hepatocytes, which catalyses the conjugation of UCB with sugar

a substantial burden, in spite of the advancement in the standard

moieties. 2 Elevations in levels of UCB up to ~300 μmol/L can lead to

treatments and care.7

bilirubin-induced encephalopathy (kernicterus) with a wide range of
irreversible neurological consequences.

3

Although earlier cohort studies have been published5,8 relevant
questions remain about CNS associated comorbidities such as cho-

Current management aims to prevent bilirubin-induced encepha-

lecystolithiasis and liver fibrosis, regional differences in treatment

lopathy by reducing serum UCB. Until the discovery of phototherapy

outcome and optimal timing of LT. Therefore, we aimed with this

4

(PT), which consists of blue light with a wavelength of 475–478 nm

worldwide cohort study to add substantial knowledge about these

and produces water-soluble photo isomers of UCB, all severely

aspects.

|
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between Fibroscan and liver histology results, liver histology was
leading.

Lay Summary
Crigler-Najjar syndrome implies a high burden for affected
patients because of the necessity of lifelong phototherapy
and/or liver transplantation. Additionally, our worldwide
registry revealed large regional differences in morbidity
and mortality rates because of inequal availability of treatment, emphasizing a high unmet medical need to improve
access to therapy. Analysis of our registry containing data
of 221 patients futher showed that liver fibrosis developed
in some patients and that total bilirubin in males was higher
than in females.

Sufficient PT is defined as daily PT with special blue light fluorescent light tubes or high-intensity light-emitting diodes (LED) (emission 400–525 [peak 450–460] nm) for 6–12 h with an irradiance at
the skin surface of at least 40 μW/cm2 ∙nm, up to 100 or more and a
body exposition of at least 35%–50% (skin lamp distance should be
30–60 cm) resulting in total bilirubin (TB) ≤20 mg/dl or 340 μmoL/L.
White bed sheets and/or reflective material around the bed should
be used. Fluorescent light tubes have to be tested and changed regularly (every 4 weeks to 4 months). In case of increased TB, it is more
effective to add a PT-Slot during daytime than further expanded
nighttime-slot because PT efficiency becomes weaker over treatment time (UCB needs to recirculate into the capillaries).
The registry is still open and patient inclusion is ongoing and

2
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follow-up data of included patients are continuously updated if

M E TH O D S

available.

To collect retrospective data of CNS patients worldwide a Good
Clinical Practice (GCP) and General Data Protection Regulation

2.1 | Statistical analysis

(GDPR) compliant web-based registry platform were developed
(commercial platform Castor EDC®; https://castoredc.com). For data

Data are presented as frequency (% of total cohort), median (inter-

management, we used a pseudonymization procedure by which per-

quartile range, IQR), or mean (±standard deviation, SD). After check-

sonally identifiable information fields within the data record are re-

ing for normal distribution analysis, the independent t-test for the

placed by a pseudonym under the control of the local PI. The ethical

comparison of parametric variables between two groups was used,

committee of the Amsterdam University Medical Center (AUMC) re-

unless stated otherwise. For nonparametric variables (normal dis-

viewed and approved the study and the registry platform. Physicians

tribution not given) we performed a Mann–Whitney test. p <.05

from 16 centres (13 countries) contributed data after obtaining ap-

was considered significant. For statistical analyses, we used SPSS

proval from local ethical committees and obtaining informed con-

Statistics v25 software (IBM).

sent of patients. The study was performed in accordance with the
principles of the Declaration of Helsinki. Data collection took place
from September 2016 up to the final analysis in January 2020, inclusion of additional sites and patients is still ongoing.
At the time of inclusion, serial lifetime retrospective data of each

3
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R E S U LT S

3.1 | Cohort description

patient were captured in the registry. Data on patient characteristics
(including medical history, genetic diagnosis, clinical features, blood

At the time of analysis, the CNS World Registry contained retro-

values, fibroscan, imaging), treatment and outcome were included.

spective data of 221 CNS patients (46% females; Cohort descrip-

An overview of the registry structure is included in the Table S1.

tion, Table 1). Clinical data were mainly collected from North Africa

Included data of blood values were measured during treatment, as

n = 96 (43.4%), Europe n = 85 (38.5%), North America n = 21 (9.5%),

far as treatment was available for the individual patient. In the man-

and Middle-East/Asia n = 19 (8.6%) (Figure S1 “World Map”). All

uscript text, the number of patients of which the data were available

patients were diagnosed based on persistent high levels of UCB in

for analysis was specified. The registry was developed for sequential

serum and 83.7% by genetic analysis. The median age of the patients

updates of the cohort to facilitate a 5-yearly evaluation. The registry

was 8 (IQR 4–19, maximum 68) years. At the time of analysis, 59

will not be used to collect prospective data. For liver-transplanted

patients (26.7%) were deceased.

patients, data after LT were analysed separately for LT-outcome.
Serum liver enzymes are expressed in U/L and bilirubin in
μmol/L. Upper limits of normal (ULN) are based on average ULN

3.2 | Clinical characteristics

for standard techniques in European laboratories. Liver fibrosis was
evaluated either from liver biopsies and explanted livers by local
®

liver pathologists or by transient elastography (Fibroscan ), which
was performed according to common guidelines.9 We interpreted
a Fibroscan result ≥8 kPa as a sign of significant fibrosis (ISHAK
Fibrosis score ≥3; Metavir Fibrosis Score ≥2).10 In case of differences

The clinical characteristics of all patients are shown in Table 2. The
average serum TB level in this cohort was 299.5 ± 121.2 μmol/L (ULN
17 μmol/L) and conjugated bilirubin (CB) level 14.4 ± 13.3 μmol/L
(ULN 5.1 μmol/L). TB and CB were significantly correlated
(p < .001). From 198/221 patients (90.0%), serum bilirubin levels

1596
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TA B L E 1 Cohort description

TA B L E 2 Clinical and biochemical characteristics

Patients included

n = 221

North Africa

96 (43.4%)

Europe

85 (38.5%)

14.4 ± 13.3 (2.8 × ULN)
62.5 ± 41.8 (~1.8 × ULN)

21 (9.5%)

Middle-East/Asia

19 (8.6%)

AST [U/L]

51.9 ± 33.1 (~1.2 × ULN)

185 (83.7%)

GGT [U/L]

54.3 ± 99.3 (~1.4 × ULN)

ALP [U/L]

214.8 ± 141.9 (~1.8 ULN)

Co-morbidity

33 (14.9%)

c.1070A>G (p.Gln357Arg)

a

39.9%
7.1%

Gallstone disease

14 (6.3%)

c

4.9%

Malignancy

2 (0.9%)

c.1489delG (p.Ala497Profs*4)c

3.4%

c.222C>A (p.Tyr74Ter)b
c.1220delA (p.Lys407Argfs*5)

Abdominal ultrasound

91 (41.2%)

Gallstones or cholecystic sludge

14/91 (15.4%)

96 (43.3%)

Portal hypertension

9/91 (9.9%)

First-degree

47 (21.3%)

Bile duct dilatation

3/91 (3.3%)

Second-degree

38 (17.2%)

c.1381T>C (p.Trp461Arg)a
Consanguinity

Third-degree

2.2%

11 (5.0%)

Male

120 (54.3%)

Age [years]

8 (4–19)

Deceased

59 (26.7%)

Note: Data presented as frequency (% of the total cohort) or median
(IQR).
Abbreviation: IQR, interquartile range.

c

Direct bilirubin [μmol/L]

North America

Allele frequency (most common ones)

Missense variant.

b

299.5 ± 121.2
(17.6 × ULN)

ALT [U/L]

Genetic diagnosis

a

Serum total bilirubin [μmol/L]

Nonsense variant.

Fibroscan available
>8 kPa
Liver histology available
Fibrosis/cirrhosis (ISHAK ≥3)
Total amount of fibrosis

18/221 (8.1%)
5/18 (27.8%)
18/221 (8.1%)
3/18 (16.6%)
5/31 (16.1%)

Note: Data presented as frequency (% of the total cohort), median (IQR)
or mean ± SD (range).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GGT, gamma glutamyl transpeptidase; IQR,
interquartile range; SD, standard deviation; ULN, upper limit normal.

Deletion variant.

In some of the older patients skin problems were reported as
were available. The amount of data points per patient strongly var-

a result of the intensive PT such as skin xerosis, lichenification or

ies from 1 to 90. In 111/198 patients (66%), we collected at least

hyperpigmentation (n = 8) or even erythematous skin rash (n = 3).

three data points. The serum levels of alanine aminotransferase

One patient developed skin melanoma, but the relation with the use

(ALT) and aspartate aminotransferase (AST) were increased with

of PT remains uncertain.

62.5 ± 41.8 U/L for ALT and 51.9 ± 33.1 U/L for AST, ULN is age-
and gender-dependent around 35 and 45 U/L respectively.11 From
113/221 patients (51.1%), liver enzymes (ALT/AST) and cholestatic

3.3 | Liver fibrosis

markers (alkaline phosphatase [ALP]/gamma-glutamyl transpeptidase [GGT]) were available. Elevated ALT >2 × ULN or >70 U/L was

In 31 patients, transient elastography (Fibroscan) data (n = 18) and/

present in 43/113 (38.1%). Serum levels of GGT 54.3 ± 99.3 U/L

or liver histology (n = 18) from liver biopsies (n = 16) or liver ex-

(ULN 38–55 U/L) and ALP 214.8 ± 141.9 U/L (ULN 120 U/L) were

plant (n = 2) were available (Table 2). In 5 of 18 patients Fibroscan

both elevated, although the high standard deviation confirms a

result was >8 kPa (widely accepted as cut off for advanced fibrosis

large variability within this cohort. ALT (Figure 1; p = .543, R 2

[ISHAK Fibrosis Score ≥3]). Median Fibroscan result was 7.1 kPa with

0.003), AST and GGT (data not shown) did not correlate with TB

IQR 1.0. In two patients with a Fibroscan result >8 kPa, liver biopsy

levels. Furthermore, also CB did not correlate with AST, ALT or

was performed and confirmed fibrosis, in one it did not. In 3 of 18

GGT. The TB level in males, 316.0 ± 125.3 μmol/L, was significantly

patients advanced fibrosis or cirrhosis was detected based on liver

higher than in females 286.6 ± 116.6 μmol/L (Table 3, p = .0003).

histology (ISHAK Fibrosis Score ≥3). The two liver explant samples

Phenobarbital treatment was not associated with higher AST or ALT

were from LTs in CNS patients below 2 years and do not show any

but with higher GGT (p = .013).

fibrosis. Overall, five CNS patients out of 31 (16%) showed signs of

The most frequently reported comorbidity for longtime survi-

advanced liver fibrosis (two by histology + fibroscan, one by histol-

vors was cholelithiasis, defined as symptomatic or asymptomatic

ogy, two by fibroscan). In sub analyses including patients dependent

gallstones or gallbladder sludge, which was identified in 6.3% of all

on PT and with an age of ≥7 years at evaluation 5 out of 15 patients

patients, and seen in 15.4% (n = 14) of patients with documented

had liver fibrosis (33%). That means all patients with fibrosis had se-

abdominal ultrasound (n = 91) (Table 2).

vere phenotypes and were at least 7 years of age at analysis. The age

|
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F I G U R E 1 Correlation ALT and TB. Elevated alanine aminotransferase (ALT) (>2 × ULN) does not correlate with serum total bilirubin
levels (p = .543, R 2 0.003). ALT, alanine aminotransferase; TB, total bilirubin
TA B L E 3 Gender differences for bilirubin, AST, ALT, GGT, ALP
Total

Male

Female

M vs. F
p

Serum total bilirubin
[μmol/L]

299.5 ± 121.2 (17.6 × ULN)

316.0 ± 125.3 (18.6 × ULN)

286.6 ± 116.6 (16.9 × ULN)

<.001

Direct bilirubin [μmol/L]

14.4 ± 13.3 (2.8 × ULN)

16.4 ± 14.1 (3.2 × ULN)

12.9 ± 12.6 (2.5 × ULN)

.001

ALT [U/L]

62.5 ± 41.8 (~1.8 × ULN)

64.3 ± 45.6 (~1.4 × ULN)

60.7 ± 37.6 (~1.8 × ULN)

.379

AST [U/L]

51.9 ± 33.1 (~1.2 × ULN)

54.7 ± 40.8 (~1.6 × ULN)

49.0 ± 22.4 (~1.6 × ULN)

.078

GGT [U/L]

54.3 ± 99.3 (~1.4 × ULN)

63.5 ± 129.2 (~1.2 × ULN)

45.1 ± 53.9 (~1.2 × ULN)

.085

ALP [U/L]

214.8 ± 141.9 (~1.8 × LN)

222.7 ± 153.2 (~1.7 × ULN)

207.3 ± 130.6 (~2.0 × ULN)

.354

Note: Data presented as mean ± SD.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; SD,
standard deviation; ULN, upper limit normal.

of the patients at fibrosis evaluation did not differ between those

(n = 37, 16.7%). Amongst patients treated with PT alone, two sub-

with or without, however, AST was significantly higher in the fibrosis

groups were identified with distinctly different treatment outcomes.

group (p = .048). Further results are shown in Table 4. Three of the

A subgroup of patients (n = 75) requiring PT, but with inadequate

five patients with fibrosis had ultrasound-proven gallstones.

access to equipment of sufficient quality, maintained high TB levels
(443.6 ± 141.4 μmol/L) and showed high morbidity with 42% of pa-

3.4 | Treatment strategies and outcomes

tients with neurologic symptoms (generalized muscle hypertonia and
dystonia, hypotonia, cerebellar dysfunctions, dysphasia) and high
mortality rates (62% deceased at a median age of 4 years). These pa-

The vast majority of patients was reported to receive treatment

tients were identified first by the fact that they had TB levels above

(95.9%) aiming to reduce UCB and prevent bilirubin-induced enceph-

the targeted limit and second by living in a similar region. On the

alopathy (Table 5; Figure 2). A small fraction of patients remained

contrary, within the group of patients (n = 57) that received lifelong

untreated (3.2%) or it is unknown if they were treated (<1%).

high standard PT based on existing recommendations12 (daily expo-

Phototherapy was the most abundantly used treatment (Table 5),

sure 9.3 ± 2.3 h), TB was adequately reduced to 298.3 ± 90.3 μmol/L

either as a monotherapy (n = 132, 59.7%) or in combination with PB

and the majority survived (92.9%), most of them reaching adulthood

18.49/14.75/13.15–43.81
(n = 22)
21.66/20.69/18.57–24.75
(n = 16)

3 female (60%)

51.20/04.00/26.85–75.55
(n = 5)

65.80/70.00/35.93–95.67
(n = 5)

81.60/35.00/−24.95 to 188.15
(n = 5)

322.60/305.00/203.82–4 41.38
(n = 5)

12.67/13.00/1.47–23.87
(n = 3)

21.20/19.82/16.48–25.91
(n = 5)

Sex

AST

ALT

GGT

Total bilirubin

Conjugated
bilirubin

Body-mass-index
(kg/m2)

21.97/20.28/18.13–25.81
(n = 13)

19.63/16.00/14.00–25.25
(n = 14)

341.22/328/271.56–410.99
(n = 15)

57.00/44.50/23.15–90.85
(n = 10)

53.90/46.50/34.09–73.71
(n = 10)

39.50/41.0/26.66–52.34
(n = 10)

8 female (47%)

15.06/16.00/7.87–22.26

n = 16

(C) Patients without fibrosis
and PT dependent

a

Liver fibrosis diagnosed by liver histology ISHAK Fibrosis Score ≥3 or Fibroscan ≥8 kPa.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; PT, phototherapy.

268.77/244.00/211.97–325.58
(n = 25)

48.15/27.00/26.39–69.91
(n = 20)

47.05/41.00/36.63–60.47
(n = 20)

33.10/25.50/25.41–4 0.79
(n = 20)

11 female (42%)

24.00/20.50/15.71–32.29

21.40/25.00/11.25–31.55

n = 26

n=5

Age (mean/
median/95% CI)

(B) Patients without fibrosis

Number of patients

(A) Patients with liver fibrosisa (all patients
are >7 years and PT dependent)

TA B L E 4 Thirty-one patients with available liver fibrosis analysis

23.96/25.06/18.86–29.07
(n = 9)

21.99/15.00/13.76–3 0.02
(n = 9)

335.70/345.50/266.26–4 05.14
(n = 10)

57.89/40.00/19.38–96.40
(n = 9)

50.22/46.00/29.74–70.71
(n = 9)

39.11/39.00/24.51–53.71
(n = 9)

7 female (70%)

23.20/23.00/15.88–3 0.52

n = 10

(D) Patients without fibrosis,
PT dependent and age >7

.804/.882/.641

.558/.230/.164

.254/.827/.806

.377/.806/.739

.153/.391/.257

.048/.269/.256

.648/.172/.854

Mann–Whitney-U-Test A
vs. B/A vs. C/A vs. D
p

1598
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TA B L E 5 Treatment and outcome
Number (% of
cohort)

Serum total bilirubin
[μmol/L]

Neurologic
symptoms

Deceased

Age at
death

Phenobarbital (PB) (monotherapy)

15 (6.8%)

146 ± 77.6
(8.6 × ULN)

0/15

0

n.a.

Phototherapy (PT) (monotherapy)

132 (59.7%)

n.a.

n.a.

n.a.

n.a.

Indicated but insufficient access

75 (34%)

443.6 ± 141.4
(26.1 × ULN)

32/75 (42.7%)

47 (62.7%)

4.0 (0–11)

Sufficient access with average daily
exposure to PT of 9.3 ± 2.3 [h]

57 (26%)

298.3 ± 90.3
(17.6 × ULN)

5/56 (8.9%)

4 (7.1%)

14.0 (1–31)

Combination therapy PB and PT with daily
exposure to PT of 9.6 ± 2.9 [h]

37 (16.7%)

289.4 ± 119.5
(17.0 × ULN)

5/37 (13.5%)

0

n.a.

Liver transplantation

26 (11.8%)

20.3 ± 26.0
(1.2 ULN)

3/26 (11.5%)

6 (23.0%)

10.0 (0–23)

Note: Data presented as frequency (%), mean ± SD or median (spread).

and stenosis of the biliary anastomosis (n = 3), leading to a total of three
re-LTs. Six of the 26 LT patients are deceased at the time of this analysis, only two of them are related to CNS (severe encephalopathy). A
detailed description of the LT patients is given in Table S2.
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DISCUSSION

Crigler-Najjar syndrome requires lifelong treatment to prevent lethal brain damage. Even though several cohort studies have been
published, additional insight into the natural course of the disease,
incidence of complications and outcome of different treatment
F I G U R E 2 Treatment strategies. Data presented as percentage
of the complete cohort (%). Unknown <1%

strategies remains valuable. We aimed to address some of the re-

without signs of bilirubin encephalopathy. Of the four patients in this

of our study made it possible to show regional differences in disease

group who passed away, only in one case the cause of death could be

occurrence, genetic background and treatment outcome, all relevant

directly attributed to CNS (neurotoxicity).

to improve the care for CNS patients.

maining questions by reporting data from the largest multicenter cohort study of CNS patients (n = 221) to date. The worldwide nature

A subgroup of patients was treated with a combination of PT and
PB (n = 37, 16.7%). When comparing the outcome with the group
that received only PT, the daily exposure time and serum TB levels

4.1 | Genetic analyses

were similar (Table 5). The incidence of neurologic symptoms (13.5
vs. 8.9%) tended to be higher for PT + PB than PT alone (Table 5).

Sequencing of the UGT1A1 gene in 185 patients (83.7% of the co-

PB monotherapy was used to treat a small group of patients in

hort) revealed several frequently occurring pathogenic variants

the described cohort (n = 15, 6.8%). The vast majority of this group

(Table 1) pointing towards a significant founder effect. The most

comprises patients with a less severe phenotype (n = 12, 80%), for-

striking being the p.Gln357Arg (c.1070A>G) reported in Tunisia,

merly called CNS type 2, with some residual UGT1A1 activity, ex-

a variant that appeared 32 generations ago.13 This founder effect

plaining their lower average serum TB levels (146 ± 77.6 μmol/L).

and the frequent consanguineous marriages that occur in Tunisia

The most frequently reported co-medication in the whole cohort
was ursodeoxycholic acid in 32 patients (14.5%).

explain the higher prevalence of eight CNS patients per million
inhabitants in this country compared to the frequency of <1 per

Twenty-six patients (11.8% of the cohort, 12.4% of patients with

million in Western Europe. Indeed, consanguineous unions range

severe phenotype) underwent LT, which resulted in a marked reduction

between 25% in Central Tunisia14 to 60% in rural areas.15 Additional

of serum TB (20.3 ± 26.0 μmol/L). The median age at LT was 9 years,

frequently found variants that have been previously reported were

ranging from 0 to 32 years of age. Procedure-related complications

identified, such as the p.Tyr74* (c.222C>A) variant seen in the Amish

(n = 13) were reported in 6/11 patients (unknown in 15 patients). The

population8,16 and the p.Lys407Argfs*5 (c.1220delA) variant seen in

most common complications were stenosis of the hepatic artery (n = 4)

the South-Western region of the Netherlands.17
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4.2 | Blood values

of patients with fibrosis evaluation (n = 31 overall and n = 15 severe phenotypes and age ≥7). We found in 31 patients with liver

Mildly elevated liver tests (ALT, AST, GGT, AP) are frequently identi-

fibrosis evaluation (liver histology or Fibroscan) five patients (16%)

fied in CNS patients. More than a third of CNS patients were de-

with signs of advanced liver fibrosis. Only higher AST was associ-

tected to have elevated ALT >70 U/L or >2 × ULN. We could show

ated with fibrosis. Except differences for body-mass-index (as an

that serum levels of AST, ALT and GGT were neither correlated with

indicator for steatohepatitis), we cannot exclude all other causes of

TB nor with CB. But AST, and in a subgroup also ALT, were associ-

fibrosis in these five patients. Since liver fibrosis is only described

ated with advanced fibrosis. We found significant higher TB (and CB)

in patients with the severe phenotype and development of fibrosis

blood levels in male CNS patients compared to female CNS patients.

is unlikely in early childhood we further focused on patients with

However, higher UCB levels in males are reported for a disease with

these characteristics (PT dependent and ≥7 years of age). This led

slightly reduced UGT1A1 activity (Gilbert syndrome) for a long time

to the prevalence of fibrosis in 33% (5/15) of this sub-analysis. This

already. First, this phenomenon was described in rats18 and thereaf-

is still less than described by Mitchell et al. 30 However, this study is

ter in a U.S. population study
with Gilbert syndrome.

20

19

and a large Italian cohort of patients

based on a cohort with low genetic diversity compared to our co-

For CNS patients, we describe this sex dif-

hort with profound genetic diversity. The causes for liver fibrosis

ference for the first time. In Gilbert syndrome this difference is ex-

in CNS patients are still unclear. Even though CNS is not a chole-

plained by the influence of sex steroids on UGT1A1 activity.18,21,22

static disease based on primary pathophysiology and textbook

In CNS, the difference cannot fully be explained by this mechanism

knowledge it is increasingly recognized, that liver histology shows

since in most patients, it is impossible to increase UGT1A1 activity,

cholestatic-like aspects and that prevalence of cholecystolithiasis

which is shown by failed treatment with PB. However, gender differ-

and sludge is higher than in the general population. Furthermore,

ences for TB in healthy adults are described and higher total heme

elevated GGT and even CB elevation is observed in a substantial

content in males compared to females may partially contribute to this

amount of CNS patients. Therefore, one cause for liver fibrosis

23,24

Though

could be subclinical cholestasis. But neither CB nor GGT was asso-

the gender difference which is described in healthy adults23,24 is

ciated with fibrosis or with each other. Additionally, the increased

smaller than in our cohort.

CB levels could be caused by interference with the high levels of

since bilirubin is the major metabolic product of heme.

UCB (falsely high) and not by cholestasis. UCB covalently bound to
albumin (delta-bilirubin) or bilirubin photo isomers, or a combina-

4.3 | Cholelithiasis

tion of both may result in an overestimation of CB levels. 32 This is
supported by the observation that CB did not correlate with AST,

A high prevalence of cholelithiasis has been reported in patients
8

ALT or GGT in our cohort and that CB was significantly correlated

with severe CNS. UCB in bile can promote gallstone formation, for

with TB and showed the same sex difference (significant higher

instance as a nucleating factor for cholesterol gallstones as indicated

levels in male patients).

by their central pigment-protein nidus. 25 In normal bile, the amount

Another cause for liver fibrosis could be a direct hepatotoxic ef-

of UCB is very low but in the bile of patients treated by PT, water-

fect of UCB mediated by photo isomers or by PT products. This has

soluble UCB photo isomers are excreted into the bile. These can par-

not been reported so far,33,34 although in vitro studies have shown

tially revert back into UCB that can form crystals inducing gallstone

that high levels of UCB impair mitochondrial membranes and these

formation. Whilst the prevalence of gallstone disease reported in

could play a role in both brain and liver damage.35 If this hypothesis

our cohort (6.3% overall; 15.4% in patients with documented ultra-

holds true, higher UCB or TB levels should correlate with AST/ALT

sound) is significantly higher compared to the estimated prevalence

or fibrosis, but we did not find such a correlation (Figure 1) and thus,

in the normal population (0.2%–1.9%), 26–28 it is not nearly as high

our data cannot support this mechanism.

as reported previously for CNS (43%).12 Reasons for this relatively

A recent study36 showed in a mouse model with reduced

lower prevalence in our cohort could be under-reporting or the

UGT1A1 activity that the liver is more vulnerable and that UCB

limited use of ultrasound screening, but also the preemptive use of

leads to an increase in inflammatory markers and upregulates the

ursodeoxycholic acid (14.5%) in some regions. The use of PB as an

activity of Kupffer and stellate cells. This is an important point

activator of the constitutive androstane receptor could also prevent

that should be verified in the CNS mouse or rat model. However,

gallstones and could have a protective effect since it leads to a shift

the results of this study are contrary to a large amount of studies

in the bile acid synthesis.

29

that showed that UCB has a substantial anti-inflammatory and anti-
oxidative effect.37–39 One could argue that not the bilirubin itself
is protective but the enzyme heme oxygenase-1, which is respon-

4.4 | Liver fibrosis

sible for bilirubin formation, and which has been shown to have an
antifibrogenic effect, harbours this function.40–42 However, Tang
30

et al.43 showed that cultured hepatic stellate cells (HSC), if exposed

even though in relevant rodent models liver fibrosis has not been

to bilirubin, have reduced inflammatory activation. Activated HSC

observed. 31 Our analyses on fibrosis is limited by the small number

is known to be involved in liver fibrosis. Lanone et al.44 could even

Liver fibrosis in CNS patients is an increasingly observed issue

|
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show in Gunn rats (the primary CNS animal model) that they are
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4.6 | Treatment and outcome, still much to improve

more resistant to endotoxin-induced hypotension and death than
non-hyperbilirubinemia rats.

CNS patients are dependent on treatment, whether this is oral

That in our small subcohort of fibrosis evaluated patients only

PB, daily PT or LT. The clinical management of CNS patients in the

patient with PT showed fibrosis is most likely caused because of

United States is well described8 and has been adopted (and adapted)

the more severe phenotype in these patients but an association

in most countries. Recent detailed studies evaluating the efficacy of

between long-term PT use and development of fibrosis cannot be

PT provided valuable guidelines for optimal treatment.12

excluded based on our data.
All these controversial and unclear aspects display the importance of liver fibrosis evaluation in the standard care of CNS pa-

4.6.1 | Lifelong PT has a favourable outcome

tients. Better detection and characterizing of liver fibrosis in CNS
patients is necessary to gain an understanding of aetiology, to iden-

A group of patients (n = 57) in our cohort received life-long high

tify patients at risk, to develop individual treatment plans (e.g. LT

standard PT, which adequately reduced TB levels to <300 μmol/L.

vs. gene therapy in the future) and to probably find a way to avoid

With a survival rate of >92% and a significant number of patients

the development of fibrosis. It may be necessary to also evaluate

that currently live in their fourth decade without bilirubin encepha-

patients with a milder phenotype who are not PT dependent for liver

lopathy, this treatment option has shown to be safe and effective.

fibrosis. Furthermore, it could be helpful to test CNS patients for ad-

In five cases, neurologic symptoms of bilirubin encephalopathy did

ditional genetic modulators (e.g. heterozygote pathogenic variants

arise and four patients died with at least one death that can be di-

in genes for CFTR [Cystic Fibrosis Transmembrane Conductance

rectly attributed to CNS (bilirubin encephalopathy). Although there

Regulator] or MDR3 [multidrug resistance protein 3]) by whole ge-

is a concern about the loss of efficacy of PT over time because of

nome or exome sequencing more frequently in future.

skin lichenification and decreasing body surface area-to-weight
ratio, 5 the outcomes of long-term PT are favourable. However, daily

4.5 | Natural course of the disease

PT with a mean exposure time of 9.3 h per day has a major impact
on the quality of life of patients. This represents a heavy burden,
requiring dedicated compliance of the patient and families. In some

Of the seven CNS patients firstly described in 1952, six died in

patients, the life-long PT was associated with skin damage (12.8%)

early childhood from bilirubin-induced encephalopathy (ker-

and in one patient developed skin cancer (melanoma) that has not

nicterus).1 Since the introduction of PT and the progress in the

been described previously in CNS. A causal relationship between

field of LT, CNS patients can now reach adulthood without brain

long-term PT and skin cancer cannot be established at this time, but

damage. But still, a significant subset of patients (n = 75) requiring

in older units, UV light was not completely absent. The complete

PT had inadequate access to treatment, because of a multitude of

absence of UV light in the current PT light sources, such as LED,

factors (geographic factors, such as great distance between home

makes the increased risk for skin cancer unlikely, though LED eye

and hospital in rural areas; economic factors; system of health care

protection is important.

and health insurance). This resulted in high serum TB levels and
in extremely high mortality and morbidity rates, which could be
underestimated because of missing data on neurologic symptoms
in at least 33 cases and loss of follow up in 10 cases. The likely sad
reality is that the subset of patients with no access to therapy rep-

4.6.2 | The combination of phototherapy with
phenobarbital might not benefit patients without
residual UGT1A1 activity

resents the natural history of untreated CNS, which is associated
with a life expectancy of 4 years (median age at death). This study

Phenobarbital increases the transcription of the UGT1A1 gene which

is the first study, which can clearly show the extraordinary regional

results in higher UGT1A1 mRNA and protein levels in the liver and

differences of treatment quality in CNS and its devastating conse-

therefore lowers the serum bilirubin levels in patients with residual

quences. The differences are not explained by delayed diagnosis

UGT1A1 activity. Patients that lack residual UGT1A1 activity have

(the symptom icterus is obvious and the indication for PT is not de-

no benefit of PB treatment additionally to their PT. Therefore the

pendent on the diagnosis of CNS) or general knowledge gaps, but

use of PB is not recommended in these patients.

instead by mundane factors like poverty, poor access to electricity
(for PT), limited availability of home PT systems and inadequate
medical infrastructure to support LT. This underlines the need to
eliminate these socioeconomic barriers or get high-quality PT units
into resource-limited settings to improve the overall outcome for

4.6.3 | Liver transplantation, high overall survival,
but are we underestimating procedure-related
complications?

CNS patients worldwide. Furthermore, new treatment approaches
should be aware of these problems and should target to overcome

Besides a uniform strong rationale to perform LT before the onset

these barriers.

of irreversible bilirubin encephalopathy and when TB levels rise to

1602

|

ARONSON et al.

dangerous levels (>400 μmol/L) despite optimal PT, other factors

In conclusion, we report the data on the CNS World Registry

such as availability of donor livers or country-specific local expertise

that harbours the largest cohort of CNS patients to date and gives

and differences in management guidelines lead to the variability of

a unique insight into the natural course of the disease, its co-

LT timing. Within our cohort, 26 patients received LT that was cura-

morbidities, including liver fibrosis, and regional differences in treat-

tive in all patients with available follow-up. An overview of these 26

ment outcomes. The study showed us that better characterization

patients is given in Table S2. Procedure-related complications were

of patients including liver fibrosis evaluation is necessary to increase

reported in 6/11 patients (unknown in 15 patients). Six patients are

our understanding of aetiology. Liver fibrosis and quality of life

deceased at the time of analysis, but none of them were related to

questionnaires should be implemented in the standard care of CNS

LT or immune suppressive therapy. However, a complication rate of

patients. The burden of this disease is high and there is an urgent

54% is at the high end of the spectrum compared to previous reports

need to globally expand the access to therapy and to develop novel

and indeed 10-year post-transplant survival rates of up to 96% have

treatment options that further improve complication-free survival

been documented.7 A limitation of the current study is the under-

and quality of life of affected patients.

representation of the patients that received a liver transplant and
the limited follow-up data after transplantation. So far, the data of

AC K N OW L E D G E M E N T S

the registry cannot answer the question, if an early (pre-emptive) or
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late LT is more favourable for the patient´s outcome.

French Crigler-Najjar Patient Association and the Italian Crigler-
Najjar Patient Association CIAMI for their support, all physicians

4.7 | Disease burden and future perspective

that collaborated to this project and included clinical data (additional
to the authors: Dr. Belbouab, Mustapha Pacha University Hospital,
Sidi M'Hamed, Algeria; Prof. Indolfi, Meyer Children's Hospital

In patients with severe phenotype, the lifetime dependency on PT

Florance, Italy; Prof. Pawlowska, Children's Memorial Health

or LT has a major impact on the quality of life. Even though differ-

Institute, Warsaw, Poland) and the patients who kindly accepted

ent treatment options exist in most regions, 59 patients from the

to contribute to the CN World Registry. Interested to participate in

registry died, of which a substantial part before adulthood and the

the CN World Registry project? Please visit the site of one of the

majority coming from regions where access to treatment is limited.

involved patient organizations via the CureCN homepage (https://

Unfortunately, we have no detailed information on the causes of

curecn.eu/partners/cn-pa) for more information or send an email to

death for most of them. A recent publication confirms the general

Piter Bosma (p.j.bosma@amsterdamumc.nl).

struggle with PT adherence and its emotional impact on children
and their parents, who face limitations in social interactions and
7

C O N FL I C T O F I N T E R E S T

may feel stigmatized by their appearance. The impact of CNS and
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the burden of the cumbersome treatment on the quality of life
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clares any conflicts of financial interest.

treatment options that are safer and curative, especially in regions
with limited access to the current standard of care. In vivo gene
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follow-u p data reveal safe and persistent phenotype correction of
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